WI Harper Group-backed XWPharma Initiates First-in-Human Studies of Treatment-Resistant Depression and Chronic Pain Therapy

WI Harper Group | September 13, 2021 | Source: XWPharma WWI Harper-backed XWPharma, a biopharmaceutical company dedicated to the discovery and development of therapeutics, announced its first-in-human study evaluating XW10508 – the Company’s novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of depression and chronic…